
Palonosetron vs. Granisetron for Chemotherapy-Induced Nausea and Vomiting in Pediatric Osteosacroma
How to Cite
OrthoEvidence. Palonosetron vs. Granisetron for Chemotherapy-Induced Nausea and Vomiting in Pediatric Osteosacroma. ACE Report. 2022;255(3):27. Available from: https://myorthoevidence.com/AceReport/Report/14645
Does a single dose of palonosetron have any role in preventing acute chemotherapy-induced nausea and vomiting in pediatric osteosarcoma patients without dexamethasone? A randomized clinical trial
Adv Clin Exp Med. 2022 01-Mar;():. 10.17219/acem/142332Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
200 pediatric osteosarcoma patients were randomized to receive a single intravenous dose of palonosetron or granisetron for antiemetic prophylaxis. The primary outcome was patient response to treatment in the first 24 hours after chemotherapy (complete response; partial response; failure). Adverse events were also recorded. Results found that patients who received palonosetron had a significantly ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!


Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.
LEARN MORE
Please Login or Join to leave comments.